JP2018512168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512168A5 JP2018512168A5 JP2017564951A JP2017564951A JP2018512168A5 JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5 JP 2017564951 A JP2017564951 A JP 2017564951A JP 2017564951 A JP2017564951 A JP 2017564951A JP 2018512168 A5 JP2018512168 A5 JP 2018512168A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- claudin
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157911.7A EP3064507A1 (en) | 2015-03-06 | 2015-03-06 | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| EP15157911.7 | 2015-03-06 | ||
| PCT/EP2016/054729 WO2016142314A1 (en) | 2015-03-06 | 2016-03-07 | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512168A JP2018512168A (ja) | 2018-05-17 |
| JP2018512168A5 true JP2018512168A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
| JP6757338B2 JP6757338B2 (ja) | 2020-09-16 |
Family
ID=52629425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564951A Expired - Fee Related JP6757338B2 (ja) | 2015-03-06 | 2016-03-07 | 結合タンパク質と、ＩＬ１５Ｒαに対する低下した親和性を有するインターロイキン１５ポリペプチドとを含む融合タンパク質、及び、その治療的使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10906952B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3064507A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6757338B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107636015A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017018975A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2978808A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1122494T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3265478T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2763598T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20192190T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE047818T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3265478T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3265478T (cg-RX-API-DMAC7.html) |
| RS (1) | RS59658B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3265478T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016142314A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| CN106380521B (zh) | 2015-07-02 | 2020-12-29 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| EP3430058A4 (en) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF |
| AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| PE20240950A1 (es) * | 2016-10-14 | 2024-05-06 | Xencor Inc | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117384929A (zh) | 2017-03-27 | 2024-01-12 | 新加坡国立大学 | 一种编码由细胞表达的嵌合受体的多核苷酸 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR20250056192A (ko) | 2017-08-07 | 2025-04-25 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME |
| CA3076014A1 (en) * | 2017-09-29 | 2019-04-04 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| TWI834636B (zh) * | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| PE20201342A1 (es) * | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| IL278090B2 (en) | 2018-04-18 | 2024-07-01 | Xencor Inc | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof |
| WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
| CN112368015B (zh) * | 2018-06-18 | 2025-04-29 | 安维达生物科技公司 | 细胞因子融合蛋白及其用途 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847196A4 (en) * | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
| KR20250154552A (ko) | 2018-09-27 | 2025-10-28 | 실리오 디벨럽먼트, 인크. | 마스킹된 사이토카인 폴리펩타이드 |
| MA53862A (fr) | 2018-10-12 | 2022-01-19 | Xencor Inc | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| CN114286683B (zh) * | 2019-07-17 | 2024-10-01 | 新加坡国立大学 | 由免疫细胞合成和分泌的功能性结合物 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN111690068B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| CN116406380A (zh) * | 2020-09-17 | 2023-07-07 | 上海霖羲致企业管理有限公司 | 双特异性重组蛋白及其用途 |
| AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| KR20230113581A (ko) | 2020-11-25 | 2023-07-31 | 실리오 디벨럽먼트, 인크. | 종양 특이적 절단성 링커 |
| CN117186227A (zh) * | 2020-12-23 | 2023-12-08 | 瑞泽恩制药公司 | 编码锚修饰的抗体的核酸以及其用途 |
| BR112023027305A2 (pt) | 2021-06-23 | 2024-03-12 | Cytune Pharma | Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
| WO2023280287A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Interleukin-15 variants and uses thereof |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN113956346B (zh) * | 2021-10-26 | 2024-03-01 | 西安龙腾景云生物科技有限公司 | 一种重组白介素-15变体 |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| WO2024085166A1 (ja) * | 2022-10-19 | 2024-04-25 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| CN120693344A (zh) * | 2023-02-14 | 2025-09-23 | 德国癌症研究公共权益基金会 | 具有改善的特性的il-15融合蛋白 |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2025147512A1 (en) * | 2024-01-02 | 2025-07-10 | Eli Lilly And Company | Immunogenicity assessment platform for biotherapeutic proteins |
| WO2025222129A2 (en) * | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| ATE516305T1 (de) * | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| MX2007006832A (es) | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| MX2009001203A (es) | 2006-08-01 | 2009-06-01 | Pieris Ag | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. |
| JP5501222B2 (ja) * | 2007-05-11 | 2014-05-21 | アルター・バイオサイエンス・コーポレーション | 融合分子及びｉｌ−１５変異体 |
| US20120196310A1 (en) | 2009-10-02 | 2012-08-02 | Christiane Jaeger | A-fucosylation detection in antibodies |
| DK2990798T3 (da) | 2009-12-07 | 2019-12-02 | Pieris Pharmaceuticals Gmbh | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål |
| EP2918607B1 (en) | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| CA2859767C (en) | 2011-12-19 | 2018-09-11 | Synimmune Gmbh | Bispecific antibody molecule and use thereof for treatment of proliferative disease |
| US10202433B2 (en) | 2013-06-27 | 2019-02-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
-
2015
- 2015-03-06 EP EP15157911.7A patent/EP3064507A1/en not_active Withdrawn
-
2016
- 2016-03-07 CN CN201680025275.8A patent/CN107636015A/zh active Pending
- 2016-03-07 HU HUE16708154A patent/HUE047818T2/hu unknown
- 2016-03-07 PL PL16708154T patent/PL3265478T3/pl unknown
- 2016-03-07 HR HRP20192190TT patent/HRP20192190T1/hr unknown
- 2016-03-07 PT PT167081546T patent/PT3265478T/pt unknown
- 2016-03-07 CA CA2978808A patent/CA2978808A1/en active Pending
- 2016-03-07 JP JP2017564951A patent/JP6757338B2/ja not_active Expired - Fee Related
- 2016-03-07 SI SI201630550T patent/SI3265478T1/sl unknown
- 2016-03-07 WO PCT/EP2016/054729 patent/WO2016142314A1/en not_active Ceased
- 2016-03-07 EP EP16708154.6A patent/EP3265478B1/en not_active Revoked
- 2016-03-07 DK DK16708154.6T patent/DK3265478T3/da active
- 2016-03-07 RS RS20191593A patent/RS59658B1/sr unknown
- 2016-03-07 ES ES16708154T patent/ES2763598T3/es active Active
- 2016-03-07 US US15/556,282 patent/US10906952B2/en not_active Expired - Fee Related
- 2016-03-07 BR BR112017018975-5A patent/BR112017018975A2/pt not_active Application Discontinuation
-
2019
- 2019-12-11 CY CY20191101303T patent/CY1122494T1/el unknown
-
2020
- 2020-12-22 US US17/130,975 patent/US20210163564A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/565,942 patent/US20220324931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512168A5 (cg-RX-API-DMAC7.html) | ||
| HRP20192190T1 (hr) | Fuzijski proteini koji sadrže vežući protein i polipeptid interleukin-15 sa smanjenim afinitetom za il15ra i njihova upotreba u terapiji | |
| JP2015502373A5 (cg-RX-API-DMAC7.html) | ||
| JP2014088414A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531093A5 (cg-RX-API-DMAC7.html) | ||
| JP2021054859A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516789A5 (cg-RX-API-DMAC7.html) | ||
| AR120585A1 (es) | Proteínas de unión a antígenos que se unen específicamente a mage-a | |
| JP2017504577A5 (cg-RX-API-DMAC7.html) | ||
| JOP20200206A1 (ar) | أجسام مضادة لألفا بروتين منظم للإشارة وطرق لاستخدامها | |
| JP2018523485A5 (cg-RX-API-DMAC7.html) | ||
| HRP20170658T1 (hr) | Molekula bispecifičnog protutijela | |
| JP2014518615A5 (cg-RX-API-DMAC7.html) | ||
| JP2018526970A5 (cg-RX-API-DMAC7.html) | ||
| JP2023052263A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| JP2019516665A5 (cg-RX-API-DMAC7.html) | ||
| RU2018109350A (ru) | Химерный цитокиновый рецептор | |
| JP2019519227A5 (cg-RX-API-DMAC7.html) | ||
| JP2018519296A5 (cg-RX-API-DMAC7.html) | ||
| JP2020503891A5 (cg-RX-API-DMAC7.html) | ||
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| MY198621A (en) | T cell receptors | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека |